Floatz logo

Regorafenib

Metastatic Colon Adenocarcinoma

City of Hope Medical CenterSmall moleculePhase 3Active
BB
68/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
54/ 100
Competitive Position
95/ 100

Competitive context

8 Active assets in the Metastatic Colon Adenocarcinoma cohort.

Asset / SponsorPhaseRating
Nivolumab
IFOM ETS - The AIRC Institute of Molecular Oncology
Phase 3BB
Encorafenib
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Phase 2/3BB
Trifluridine
Academic and Community Cancer Research United
Phase 2BB
TIPIRACIL
Academic and Community Cancer Research United
Phase 2BB
VOLITINIB
National Cancer Institute (NCI)
Phase 2CCC

View all 10 →

Same molecule, other indications

Regorafenib is also rated in:

gastrointestinal stromal tumorDormant
BBB
Indicative ·
73 / 100
View asset →
colorectal neoplasmDormant
BB
Indicative ·
71 / 100
View asset →
RegorafenibDormant
BB
Indicative ·
70 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →